Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31584710 | 1.00 | NAAA (0.52) | NAAATSHREPHX1HTR2CHCAR2 | |
| SCHEMBL31584796 | 1.00 | NAAA (0.52) | NAAATSHREPHX1HTR2CHCAR2 | |
| SCHEMBL31584462 | 1.00 | NAAA (0.52) | NAAATSHREPHX1HTR2CHCAR2 | |
| SCHEMBL18672810 | 1.00 | NAAA (0.52) | NAAATSHREPHX1HTR2CHCAR2 | |
| SCHEMBL2214927 | 1.00 | NAAA (0.52) | NAAATSHREPHX1HTR2CHCAR2 | |
| SCHEMBL7781605 | 1.00 | NAAA (0.52) | NAAATSHREPHX1HTR2CHCAR2 | |
| SCHEMBL7782136 | 1.00 | NAAA (0.52) | NAAATSHREPHX1HTR2CHCAR2 | |
| SCHEMBL2214933 | 1.00 | NAAA (0.52) | NAAATSHREPHX1HTR2CHCAR2 | |
| SCHEMBL7782139 | 1.00 | NAAA (0.52) | NAAATSHREPHX1HTR2CHCAR2 | |
| SCHEMBL7782944 | 1.00 | NAAA (0.52) | NAAATSHREPHX1HTR2CHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113677337-B | Cationic compositions based on self-neutralizing amino acids | 伊诺莱克斯投资公司 | 2025-05-23 | — | — | CN | claimed |
| US-20230092150-A1 | Self-Neutralizing Amino Acid Based Cationic Compositions | INOLEX INVESTMENT CORPORATION | 2023-03-23 | — | — | US | claimed |
| US-11540991-B2 | Self-neutralizing amino acid based cationic compositions | INOLEX INVESTMENT CORPORATION (US) | 2023-01-03 | — | — | US | claimed |
| EP-3934638-A1 | SELF-NEUTRALIZING AMINO ACID BASED CATIONIC COMPOSITIONS | Inolex Investment Corporation (US) | 2022-01-12 | — | — | EP | claimed |
| US-20200281830-A1 | Self-Neutralizing Amino Acid Based Cationic Compositions | INOLEX INVESTMENT CORPORATION (US) | 2020-09-10 | — | — | US | claimed |
| US-20230255202-A1 | ANTIMICROBIAL COMPOSITION | THE PROCTER & GAMBLE COMPANY | 2023-08-17 | — | — | US | disclosed |
| US-20230092150-A1 | Self-Neutralizing Amino Acid Based Cationic Compositions | INOLEX INVESTMENT CORPORATION | 2023-03-23 | — | — | US | disclosed |
| US-11540991-B2 | Self-neutralizing amino acid based cationic compositions | INOLEX INVESTMENT CORPORATION (US) | 2023-01-03 | — | — | US | disclosed |
| EP-3934638-A1 | SELF-NEUTRALIZING AMINO ACID BASED CATIONIC COMPOSITIONS | Inolex Investment Corporation (US) | 2022-01-12 | — | — | EP | disclosed |
| US-20200281830-A1 | Self-Neutralizing Amino Acid Based Cationic Compositions | INOLEX INVESTMENT CORPORATION (US) | 2020-09-10 | — | — | US | disclosed |
| EP-1135398-A1 | CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION | Monsanto Technology LLC (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6218563-B1 | Cyanophosphonamides and method for preparation | MONSANTO COMPANY | 2001-04-17 | — | — | US | disclosed |
| WO-2000032611-A1 | CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION | MONSANTO TECHNOLOGY LLC (US) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200281830-A1 | Self-Neutralizing Amino Acid Based Cationic Compositions | SLC6A15, SLC1A5, SLC6A19 | NAAA 31/4885TSHR 3595/4885EPHX1 2990/4885 |
| US-20230255202-A1 | ANTIMICROBIAL COMPOSITION | ARG1, CUTA, SLC7A1 | NAAA 261/4885TSHR 3822/4885EPHX1 4548/4885 |
| US-20230092150-A1 | Self-Neutralizing Amino Acid Based Cationic Compositions | SLC6A15, SLC1A5, SLC6A19 | NAAA 31/4885TSHR 3595/4885EPHX1 2990/4885 |
| US-11540991-B2 | Self-neutralizing amino acid based cationic compositions | SLC6A15, SLC1A5, SLC6A19 | NAAA 31/4885TSHR 3595/4885EPHX1 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.